Full Press Release Details
to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th
American Society of Gene & Cell Therapy Annual Meeting
NEW YORK--(BUSINESS WIRE)--May 2, 2016--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells (UCART), today announced that data on its
engineered allogeneic CAR T-cell programs will be featured in three
poster presentations at the American Society of Gene & Cell Therapy
(ASGCT) 19th Annual Meeting.
The meeting will be held from May 4 to May 7, 2016 in Washington, DC,
Allogeneic CAR T-Cells Targeting CD123 Effectively Eliminate Myeloid
Presentation by Julianne Smith, Ph.D., Vice President CART Development
Poster Session: Cancer-Immunotherapy, Cancer Vaccines II
Time: Thursday, May 5, 2016, 5:45 PM
Room: Exhibit Hall C & B South
abstract number: 397
An Engineered CAR T-Cell Platform for Allogeneic Combination
Presentation by Philippe Duchateau, Ph.D., Chief Scientific Officer of
Poster Session: Cancer-Targeted Gene and Cell Therapy II
Time: Friday, May 6, 2016, 6:00 PM - 8:00 PM
Room: Exhibit Hall C & B
Final abstract number: 676
Integration of Dual Signal Input Strategies in Novel Chimeric Antigen
Receptors to Control the CAR T-Cell Functions
Presentation by Alexandre Juillerat, Ph.D., Senior Scientist at Cellectis
Session: Cancer-Immunotherapy, Cancer Vaccines III
Friday May 6, 2016 6:00 PM - 8:00 PM
Room: Exhibit Hall C & B South
abstract number: 651
Posters will be posted on Cellectis' website on May 7, 2016.
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering - based on its flagship TALEN
products and meganucleases and pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis is listed on
the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market
(ticker: ALCLS). To find out more about us, visit our website:
Talking about gene editing? We do it.
TALEN is a registered
trademark owned by the Cellectis Group.
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
For further information, please contact:
Jennifer Moore, VP of Communications
email: media@cellectis.com
KCSA Strategic Communications
Phone: +1 212.896.1241
VP of Corporate Strategy and Finance
email: simon.harnest@cellectis.com